. Vagal cardiac function and arterial blood pressure stability. Am J Physiol Heart Circ Physiol 281: H1870-H1880, 2001.-This study was designed to investigate the importance of vagal cardiac modulation in arterial blood pressure (ABP) stability before and after glycopyrrolate or atropine treatment. Changes in R-R interval (RRI) and ABP were assessed in 10 healthy young (age, 22 Ϯ 1.8 yr) volunteers during graded lower body negative pressure (LBNP) before and after muscarinic cholinergic (MC) blockade. Transient hypertension was induced by phenylephrine (1 g/kg body wt), whereas systemic hypotension was induced by bilateral thigh cuff deflation after a 3-min suprasystolic occlusion. Power spectral densities of systolic [systolic blood pressure (SBP)] and diastolic ABP variability were examined. Both antimuscarinic agents elicited tachycardia similarly without significantly affecting baseline ABP. The increase in SBP after phenylephrine injection (ϩ14 Ϯ 2 mmHg) was significantly augmented with atropine (ϩ26 Ϯ 2 mmHg) or glycopyrrolate (ϩ27 Ϯ 3 mmHg) and associated with a diminished reflex bradycardia. The decrease in SBP after cuff deflation (Ϫ9.2 Ϯ 1.2 mmHg) was significantly greater after atropine (Ϫ15 Ϯ 1 mmHg) or glycopyrrolate (Ϫ14 Ϯ 1 mmHg), with abolished reflex tachycardia. LBNP significantly decreased both SBP and RRI. However, after antimuscarinic agents, the reduction in SBP was greater (P Ͻ 0.05) and was associated with less tachycardia. Antimuscarinic agents reduced (P Ͻ 0.05) the low-frequency (LF; 0.04-0.12 Hz) power of ABP variability at rest. The LF SBP oscillation was significantly augmented during LBNP, which was accentuated (P Ͻ 0.05) after antimuscarinic agents and was correlated (r ϭ Ϫ0.79) with the decrease in SBP. We conclude that antimuscarinic agents compromised ABP stability by diminishing baroreflex sensitivity, reflecting the importance of vagal cardiac function in hemodynamic homeostasis. The difference between atropine and glycopyrrolate was not significant. baroreflex gain; glycopyrrolate; power spectral analysis; lower body negative pressure; phenylephrine; suprasystolic occlusion; Valsalva maneuver; vasomotion WE RECENTLY IDENTIFIED a greater decrease in arterial blood pressure (ABP) associated with a diminished tachycardiac response at the onset of Ϫ40 Torr lower body negative pressure (LBNP) in elderly compared with young adults (21). This attenuated increase in heart rate (HR) at the onset of orthostatic challenge results primarily from an age-related diminution in vagal cardiac function (21). When the muscarinic cholinergic (MC) antagonists atropine or glycopyrrolate were administered to young subjects to block cardiac parasympathetic efferent influences, their tachycardiac response to the onset of Ϫ40 Torr LBNP was abolished. The attenuated tachycardia was associated with a significant hypotension, a response similar to that seen in the elderly individual (21). When the ␤ 1 -adrenoceptor antagonist metoprolol was administrated to the same young subjects to block the cardiac sympathetic nerve efferent influence, neither the ABP nor the HR response was affected at the onset of Ϫ40 Torr LBNP (21). However, the impact of vagal cardiac function on ABP variability during graded sustained orthostatic challenge has yet to be established.
WE RECENTLY IDENTIFIED a greater decrease in arterial blood pressure (ABP) associated with a diminished tachycardiac response at the onset of Ϫ40 Torr lower body negative pressure (LBNP) in elderly compared with young adults (21) . This attenuated increase in heart rate (HR) at the onset of orthostatic challenge results primarily from an age-related diminution in vagal cardiac function (21) . When the muscarinic cholinergic (MC) antagonists atropine or glycopyrrolate were administered to young subjects to block cardiac parasympathetic efferent influences, their tachycardiac response to the onset of Ϫ40 Torr LBNP was abolished. The attenuated tachycardia was associated with a significant hypotension, a response similar to that seen in the elderly individual (21) . When the ␤ 1 -adrenoceptor antagonist metoprolol was administrated to the same young subjects to block the cardiac sympathetic nerve efferent influence, neither the ABP nor the HR response was affected at the onset of Ϫ40 Torr LBNP (21) . However, the impact of vagal cardiac function on ABP variability during graded sustained orthostatic challenge has yet to be established.
One of the major purposes of this study was to investigate the role of the parasympathetic efferent arm of the baroreflex in maintaining ABP stability. Previously, Saul et al. (19) observed that both systolic (SBP) and diastolic blood pressure (DBP) variance increased significantly during a body postural change from supine to standing with or without cardiac autonomic blockade. However, they did not describe the changes in SBP and DBP spectral density elicited by standing (19) . Taylor et al. (24) demonstrated that the low-frequency (LF) power of ABP oscillation was significantly augmented during 40°head-up tilt. However, the augmentation in the LF power of ABP oscillation during tilt combined with atropine did not reach significance (23) , probably due to the lack of significant hypotensive challenge. This investigation was designed to further consider the relationship between hypotension and LF ABP variability during graded and sustained hypotensive stimuli before and after vagal cardiac blockade.
Atropine is a common antimuscarinic agent that has been applied to study vagal cardiac function under the influence of heart disease (7, 13, 17) and during orthostatic challenge (19, 20, 22, 24) . It has been established that baroreflex function is impaired after atropine treatment. Because atropine penetrates the bloodbrain barrier, it blocks both central and peripheral MC receptors (1, 3) and alters central autonomic nervous system activity (10, 14) . The antimuscarinic agent glycopyrrolate has little influence on the central nervous system (3) . Equipotent doses of atropine and glycopyrrolate (2, 5) were thus applied to establish the vagal cardiac contribution to ABP stability during dynamic hypertensive and hypotensive stimuli. Although previous studies have compared atropine and glycopyrrolate differences in HR response (5) and HR variability (2), we believe that this is the first study to investigate the effects of these antimuscarinic agents on the dynamic control and regulation of ABP. We hypothesized that use of antimuscarinic agents would simulate vagal dysfunction and compromise ABP regulation but that the degree of change in ABP regulation with atropine blockade would differ from that during glycopyrrolate blockade of the MC receptors.
METHODS

Subjects.
Ten disease-free and drug-free volunteers (age, 22 Ϯ 1.8 yr; n ϭ 7 men and 3 women) were recruited as subjects. On a preliminary screening day, all subjects completed a medical history questionnaire and provided a resting 12-lead electrocardiogram (ECG) and arterial blood pressure (ABP). All female subjects who participated in the study had a negative pregnancy test before the initiation of the study. Eligible subjects received both oral and written explanation of the experimental protocol and signed a written consent form that was approved by the Institutional Review Board for the Protection of Human Subjects at the University of North Texas Health Science Center (Fort Worth, TX).
Measurements. During each experiment, beat-to-beat HR, SBP, DBP, and mean ABP (MAP) signals were digitized (Vetter Digital 3000) and collected using an on-line personal computer (Gateway 2000, 486DX) interfaced by an analogto-digital board (Data Translation DT2801; Marlboro, MA) with a software sampling rate at 150 Hz. The lead II ECG signal was used to monitor HR on an electrocardiograph (Hewlett-Packard 78342A). On experimental day 1, an ABP signal was established using intraradial arterial catheterization. A physician, using local anesthesia to minimize subject discomfort, performed the catheter insertion. During experimental day 2, indirect radial tonometry (Colin 7000) was utilized. Previous data (11) indicated a close correlation between tonographic and direct ABP measurements. Our laboratory observations indicated that carefully monitored indirect measurements of radial arterial pressure by tonography were highly correlated with intraradial arterial catheter measurements (Fig. 1) . Although radial pressure signals have a tendency to amplify systolic ABP values compared with brachial or aortic pressure measurements, this effect is insignificant when the comparisons are made before and after atropine or glycopyrrolate in the same subjects. A venous catheter was inserted into the subject's median antecubital vein for intravenous drug injections and blood samples. Venous blood was collected during baseline and Ϫ40 Torr LBNP before and after drug administration for measurement of the plasma catecholamines. Each 5-ml sample was centrifuged at 4°C for 15 min and frozen at Ϫ90°C, and the supernatant was analyzed using HPLC within 2 wk. Stroke volume (SV) and cardiac output (CO) values were collected by impedance plethysmography (Minnesota Impedance Cardiograph). Minute SV was averaged from the data collected over 50 s using commercially available software (Bio-Impedance Technology; Chapel Hill, NC). Peripheral vascular resistance (PVR) was then calculated from the equation PVR ϭ MAP/ CO. A 2.8% coefficient of variation was found for SV repeatedly measured in one subject at rest on three different days. Because thoracic impedance and tonographic ABP measurements shared the same computer channel, SV and CO were only determined during the experiments in which direct ABP was monitored.
Protocol. Before each experiment, subjects were familiarized with the procedures and measurements to be used during the test. All experiments were carried out with the subject supine in the LBNP chamber, with an ambient temperature of 24-26°C. The subjects were encouraged to stay relaxed throughout the testing. After 30 min of rest, baseline values for 10 min of HR, ABP, SV, and CO were recorded. At the end of baseline data collection, bilateral thigh cuffs were inflated to Ն200 mmHg for 3 min to create regional ischemia. The tachycardiac response to a systemic hypotension after deflation of the bilateral thigh cuffs was monitored. Phenylephrine was then injected at 1.0 g/kg body wt to create transient hypertension. In addition, the Valsalva maneuver was performed in some subjects before and after parasympathetic blockade to compare the difference in hypertensive effect during the release phase (Fig. 2) .
When ABP returned to baseline, a graded LBNP test was conducted. The protocol involved 30 min of graded LBNP in progressive 10-min intervals of Ϫ40, Ϫ50, and Ϫ60 Torr. At the end of Ϫ40 Torr LBNP, blood samples were taken for epinephrine and norepinephrine concentrations. After graded LBNP, the subject was released from the LBNP box and allowed to rest for Ն45 min to allow recovery. After the subject returned to the LBNP box, either atropine or glycopyrrolate was injected intravenously (5.0 or 2.0 g/kg, respectively) to achieve full MC blockade. Injections were administered over several minutes until the subject's HR Fig. 1 . A summary of the relationship between beat-to-beat systolic (SBP) and diastolic blood pressure (DBP) measured by radial tonography and an intra-arterial catheter during 2-min baseline and Ϫ50 Torr lower body negative pressure (LBNP) conditions in one subject. Solid line, identity line.
achieved a plateau, such that two consecutive doses did not yield any additional increase in HR, or until the maximum allowable dosage (40 or 16 g/kg, respectively). Upon completion of drug injection, the above protocol was repeated in its entirety. After the experiment was concluded, the subject was observed for Ն30 min to ensure proper recovery. On the experimental day 2, the subject received either atropine or glycopyrrolate, whichever drug was not used on day 1, and the day 1 protocol was repeated. The order of the experiments using atropine or glycopyrrolate was randomly assigned.
Data management. Each 10-min data set was plotted using SigmaPlot software and examined for variance, beat-to-beat pulse interval [R-R interval (RRI)], HR, SBP, and DBP from the selected 6-min segment with the least variation. The data from the 6-min "steady-state" segment were then linearly interpolated and resampled at 2 Hz. After resampling, the data were detrended with a third-order polynomial fitting and divided into 128-point segments with 50% overlap for fast Fourier transform analysis using the templates created with the data analysis and display software (DADiSP/ AdvDSP, DSP Development; Cambridge, MA). Group power spectral density curves for RRI, SBP, and DBP variability are shown in Fig. 3 
, where ASRRI( f ) is the autospectrum RRI variability, to determine the linear relation between the signals as described previously (19, 27) . The slopes of the HR response to ABP changes after phenylephrine injection (hypertensive stimulus) and bilateral thigh cuff deflation after 3-min suprasystolic occlusion (hypotensive stimulus) were calculated as the index of baroreflex sensitivity (gain). The rate of change in ABP after hypertensive and hypotensive intervention was determined by the magnitude of the change divided by the time (t; in s).
Data are reported as group means Ϯ SE. Because only one subject completed the protocol of Ϫ60 Torr LBNP after MC blockade using atropine or glycopyrrolate, the single subject data were excluded (Table 1) . One-way (e.g., drug factor) or two-way (e.g., drug and LBNP factors) ANOVA was used to test for significance. If the ANOVA P value was Յ0.05 in drug factor (i.e., control, atropine, and glycopyrrolate) or LBNP factor (i.e., baseline, Ϫ40, Ϫ50, and Ϫ60 Torr), a post hoc test for multiple comparison of the means (Duncan's method) was applied. Simple linear regression analysis was used to test for significance in the correlation between the variables. Analysis of covariance was used to test for differences in the rate of changes for different slopes. Statistical analysis system software was used for all analyses, and significance was set at P Ͻ 0.05 for all statistical tests.
RESULTS
Baseline HR or pulse interval (RRI), SBP, DBP, MAP, pulse pressure (PP), RRI variability, and ABP variability were not different in the two experiments before MC blockade using atropine or glycopyrrolate. Thus the baseline data were combined into one baseline. Both atropine and glycopyrrolate increased the baseline HR without a significant effect on ABP (Table  1) . Previously, studies (19, 23) have shown a significant increase in ABP after atropine, whereas others (17, 22) found no significant ABP augmentation. The cause for the inconsistency is unknown. The tachycardiac effect was not different between the two antimuscarinic agents. LBNP elicited significant tachycardia associated with significant decreases in SBP and PP. However, MAP and DBP were not significantly altered by LBNP. The magnitude and the rate of decrease in PP or SBP during LBNP were greater after MC blockade with atropine or glycopyrrolate. However, this change in PP or SBP was not statistically different between atropine and glycopyrrolate ( Table 1) .
Atropine and glycopyrrolate administration produced similar reductions (P Ͻ 0.05) in the baroreflex slope (calculated from the changes in HR to SBP) during systemic hypotension induced by the bilateral thigh cuff deflation after 3-min suprasystolic occlusion and systemic hypertension induced by a phenylephrine injection of 1 g/kg body wt (Table 2 ). However, there was no drug-related difference in the baroreflex slopes between the two antimuscarinic agents. After atropine or glycopyrrolate blockade, the increase in ABP to the same dose of phenylephrine and the decrease in ABP to the same cuff deflation protocol were significantly augmented (Table 2) . (Fig. 2 ). This augmented ABP overshoot was associated with a significant diminution of the bradycardiac response (before vs. after parasympathetic blockade: ⌬RRI/t, ϩ40.6 Ϯ 7.0 vs. ϩ6.8 Ϯ 1.3 ms/s; or ⌬HR/t, Ϫ3.8 Ϯ 0.8 vs. Ϫ1.9 Ϯ 0.4 beats ⅐ min Ϫ1 ⅐ s Ϫ1 ; Fig. 2 ). Parasympathetic blockade using atropine or glycopyrrolate significantly diminished RRI variability (Fig.  3) . The density of the LF spectrum of the baseline RRI variability was significantly less after glycopyrrolate than after atropine blockade (Table 3) . After normalization with the control (before the antimuscarinic agents), this difference between atropine (Ϫ410 Ϯ 121 Table 3) . The LF spectrum of RRI variability during LBNP tended to be greater with atropine than glycopyrrolate (P ϭ 0.08). However, the changes in RRI variability during LBNP were not significantly different between atropine and glycopyrrolate. The RRI variability LFto-HF ratio was not affected by MC blockade; however, it was increased with LBNP (Table 3) . Parasympathetic blockade decreased (P Ͻ 0.05) the baseline LF ABP variability without affecting the HF ABP variability (Table 4) . Baseline LF ABP variability was significantly less after glycopyrrolate than after atropine blockade, and the effect was associated with the baseline LF RRI variability (Fig. 4) . Application of LBNP augmented both LF SBP variability (P ϭ 0.002) and LF DBP variability (P ϭ 0.001; Fig. 3 and Table 4 ). The augmented LF ABP variability during LBNP was greater after parasympathetic blockade, and the interaction of LBNP factor and drug factor (parasympathetic blockade) on both ⌬SBP variability (P ϭ 0.038) and ⌬DBP variability (P ϭ 0.020) was significant (Table 4 ). The augmented LF ABP variability was significantly associated with the LBNP-induced systemic hypotension (Fig. 5) . Figure 5 illustrates the group increases in LF SBP variability associated with decreases in SBP before and after parasympathetic blockade during graded LBNP (r ϭ Ϫ0.79, P ϭ 0.037), which was consistent with the correlation when calculated using individual data (r ϭ Ϫ0.46, P ϭ 0.001). Values are means Ϯ SE, averaged over 6 min of continuous data; n ϭ no. of subjects. After atropine or glycopyrrolate, only one subject in each group reached Ϫ60 Torr lower body negative pressure (LBNP) (data not included). RRI, R-R interval; HR, heart rate; SBP and DBP, systolic and diastolic blood pressure, respectively; MAP, mean arterial pressure; PP, pulse pressure. P values indicate two-way ANOVA outcome. * P Ͻ 0.05 vs. control group, same LBNP level, from post hoc analysis; † P Ͻ 0.05 vs. baseline within the same group. Values are means Ϯ SE; n ϭ no. of subjects. ⌬SBP/t and ⌬DBP/t, changes in SBP and DBP over time (in s), respectively; RRI/SBP and HR/SBP, baroreflex slopes calculated from the R-R interval (RRI) and HR plotted against SBP. P values indicate the ANOVA outcome for drug factor. * Significant difference from control.
Atropine tended to have a greater effect on LBNPinduced augmentation in LF ABP variability compared with the glycopyrrolate effect. However, the difference between the two drugs did not reach a significance level in ⌬SBP variability (P ϭ 0.09) or ⌬DBP variability (P ϭ 0.16). Parasympathetic blockade with atropine or glycopyrrolate significantly decreased the magnitude of the transfer function of SBP variability to RRI variability (Table 4 and Fig. 6 ). There was no difference in the abolished transfer function between the two drugs. The coherence of the transfer function at the HF spectrum disappeared after atropine or glycopyrrolate treatment. LBNP significantly decreased the HF magnitude of the transfer function in the control condition (without parasympathetic blockade) but had no apparent effect on the LF transfer function. The coherence of the transfer function during LBNP tended to increase at the LF spectrum and decrease at the HF spectrum (Table 4) .
Baseline plasma epinephrine and norepinephrine concentrations (0.43 Ϯ 0.18 and 1.42 Ϯ 0.21 pmol/ml) were not affected by atropine (0.22 Ϯ 0.07 and 1.18 Ϯ 0.33 pmol/ml) or glycopyrrolate (0.38 Ϯ 0.12 and 1.21 Ϯ 0.11 pmol/ml) blockade. LBNP (Ϫ40 Torr) did not change epinephrine (0.39 Ϯ 0.08, 0.18 Ϯ 0.05, and 0.30 Ϯ 0.01 pmol/ml in control, atropine, and glycopyrrolate, respectively) but significantly increased norepinephrine in the control (2.05 Ϯ 0.27 pmol/ml) and Values are means Ϯ SE, averaged over 6 min of continuous data; n ϭ no. of subjects. After atropine or glycopyrrolate, only one subject in each group reached Ϫ60 Torr LBNP (data not included). LF, low frequency (0.04-0.12 Hz); HF, high frequency (0.20-0.28 Hz); LFNU, normalized LF, calculated from 100 ϫ LF/(LF ϩ HF); HFNU, normalized HF, calculated from 100 ϫ HF/(LF ϩ HF). P values indicate two-way ANOVA outcome. * P Ͻ 0.05 vs. control group; † P Ͻ 0.05 for atropine vs. glycopyrrolate, post hoc analysis. Values are means Ϯ SE; n ϭ no. of subjects. P values indicate two-way ANOVA outcome. * Significant change from baseline; † P Ͻ 0.05 vs. control group; ‡ P Ͻ 0.05, atropine vs. glycopyrrolate.
MC blockade conditions (atropine and glycopyrrolate: 2.44 Ϯ 0.78 and 1.63 Ϯ 0.28 pmol/ml). The relative increase in norepinephrine during LBNP appeared to be greater (P ϭ 0.18) after atropine (ϩ108 Ϯ 25%) than glycopyrrolate (ϩ49 Ϯ 26%) compared with the responses before MC blockade (ϩ61 Ϯ 31% vs. ϩ61 Ϯ 15%, P ϭ 0.99).
There was no significant difference in CO after either atropine (n ϭ 5) or glycopyrrolate (n ϭ 3) administration. Because there was no observed drug difference and the sample size was small, CO and PVR data were merged and classified into "before" and "after MC blockade" groups. Drug administration did not significantly change CO (7.0 Ϯ 0.3 vs. 6.1 Ϯ 0.2 l/min), although SV decreased significantly from a baseline of 113 Ϯ 8.5 to 58.3 Ϯ 2.8 ml/beat after drug administration. PVR tended to increase after MC blockade (12.8 Ϯ 0.7 to 14.9 Ϯ 0.7 peripheral resistance units, P ϭ 0.06). Figure 7 shows the decrease in CO in all groups during minute 2 (before vs. after blockade: Ϫ17.5 Ϯ 2.2% vs. Ϫ29.6 Ϯ 6.4%), minute 5 (Ϫ20.3 Ϯ 2.8% vs. Ϫ34.8 Ϯ 4.5%), and minute 8 (Ϫ22.4 Ϯ 3.0% vs. Ϫ28.8 Ϯ 3.9%) of Ϫ40 Torr LBNP and minute 2 (Ϫ24.8 Ϯ 3.3% vs. Ϫ29.2 Ϯ 6.2%), minute 5 (Ϫ27.5 Ϯ 2.5% vs. Ϫ34.4 Ϯ 4.0%), and minute 8 (Ϫ28.4 Ϯ 2.4% vs. Ϫ35.4 Ϯ 5.1%) of Ϫ50 Torr LBNP, associated with a decrease in MAP (Fig. 7, left) . The changes in CO and MAP were consistently greater after MC blockade (P ϭ 0.001 from ANOVA for drug factor on %⌬CO, P ϭ 0.003 from ANOVA for drug factor on %⌬MAP), although post hoc analysis with stratification of time or LBNP did not reach significance. However, the rate of decrease in MAP per unit decrease in CO was similar to the control condition (slope ϭ 0.43 for both groups, P ϭ 0.66 from analysis of covariance). In addition, a greater relative decrease in CO was explained by a reduced tachycardiac compensation after MC blockade (Fig. 7, right) , because the decrease in CO in terms of per unit decrease in SV was greater (P ϭ 0.016 from analysis of covariance) after antimuscarinic agents.
DISCUSSION
The present study provided three new findings that extend previous observations on the importance of vagal cardiac function in maintaining ABP. First, our data manifested that MC blockade using atropine or glycopyrrolate was associated with an augmented amplitude of ABP fluctuations during dynamic hypertensive and hypotensive stimuli. These augmented ABP fluctuations were related to diminished baroreflex sensitivity. Second, our data indicated that sustained LBNP increased the LF spectral density of ABP variability and that the increased LF ABP oscillation was associated with systemic hypotension, which was augmented after MC blockade. Third, the difference in the arterial baroreflex function and ABP variability elicited by atropine and glycopyrrolate was not statistically significant. These data demonstrated that the integrity of vagal cardiac function was essential for the maintenance of ABP stability during various hemodynamic challenges.
Mechanism of the augmented amplitude of ABP variability. A previous study (8) reported that the pressor response to phenylephrine injection in tranquilized dogs was substantially augmented after atropine treatment combined with the ␤-adrenoceptor antagonist propranolol. These authors postulated that the augmented pressor response to phenylephrine after propranolol and atropine was related to the blockade of a peripheral vasodilation mechanism modulated by the ␤-adrenoceptor and the cholinergic fiber (8) . Our data and after (closed symbols) parasympathetic blockade using atropine (circles) and glycopyrrolate (squares). Shaded diamonds, group means Ϯ SE. Before parasympathetic blockade, baseline group LF SBP and RRI variability was not statistically different between atropine and glycopyrrolate. Although group LF SBP and RRI variability was significantly smaller after glycopyrrolate than atropine, the changes from the baseline at rest were not statistically different between the two drugs. Dashed line, regression line for individual data (r ϭ 0.68, P ϭ 0.001).
indicated that an augmented pressor response to phenylephrine was present after MC blockade alone with either atropine or glycopyrrolate ( Table 2 ), suggesting that the ␤-adrenoceptor mechanism of peripheral vasodilation described by Evans et al. (8) had little effect on ABP changes elicited by phenylephrine. Sanders et al. (18) reported a significant increase in forearm blood flow during contralateral arm exercise, which was attenuated after atropine. However, the overall response to exercise was an increase in MAP, indicating a limited functional significance for the cholinergic vasodilatory mechanism. Conversely, administration of atropine in conscious rats has demonstrated no effect on the resting ABP or blood flow in various tissues and organs (4) . Although species and protocol differences must be considered when interpreting these results, we believe that these previous studies and our current data suggest a minimal physiological contribution from the ␤-adrenoceptor or cholinergic fiber elicited vasodilation at rest. Furthermore, neither the previous study (8) nor the current data support the theory of a sensitized ␣-adrenoceptor mechanism in the augmented pressor response to phenylephrine. If the ␣-adrenoceptor sensitivity were enhanced by MC blockade, a hypotension or depressor response after bilateral thigh cuff inflation/deflation would be diminished after atropine or glycopyrrolate. However, MC blockade significantly exacerbated the systemic hypotension after the cuff deflation (Table 2) .
Our data demonstrated that vagal cardiac function played an important role in defending ABP fluctuations and that the diminished HR buffering effect (or baroreflex sensitivity) with MC blockade was responsible for the augmented amplitude of the pressor or depressor response during dynamic hypertensive and hypotensive stimuli elicited by the cuff deflation protocol (a nonpharmacological intervention). These data are among the first to elucidate that vagal cardiac dysfunction simulated by MC blockade with atropine or glycopyrrolate augments the amplitude of both ABP overshoot and undershoot during dynamic hypertensive and hypotensive stimuli. There was no difference in the baroreflex sensitivity and ABP changes between atropine and glycopyrrolate, which suggest that after large doses of the antimuscarinic agents, the altered parasympathetic control of HR is the mechanism responsible for the diminished baroreflex sensitivity and for the augmented amplitude of ABP fluctuations during hypertensive and hypotensive stimuli compared with the baseline condition.
LF ABP oscillations after antimuscarinic drugs. The LF spectral density of ABP variability tended to decrease after MC blockade. These data were consistent with a previous study (23) describing a significant http://ajpheart.physiology.org/ decrease in the LF power of ABP variability after atropine with or without atenolol. This diminished LF ABP oscillation was more significant after glycopyrrolate than atropine administration (Table 4 ). The mechanism underlying this difference in the LF ABP oscillation before and after the MC blockade or between the two antimuscarinic agents was associated with a low LF RRI variability (Fig. 4) .
It has been proposed that atropine administration may elicit opposing central and peripheral effects on vagal cardiac control (6, 10) . Recent human studies (14, 26) have shown that low-dose intravenous atropine injection prolongs RRI, indicating an increase in central parasympathetic activation. Atropine also decreased the LF RRI variability in these studies, associated with a reduced LF muscle sympathetic nerve activity (MSNA) variability (14, 26) . These previous data suggest that blocking central MC receptors with atropine releases the central inhibitory influence on peripheral sympathetic nerve activity. However, this central influence on HR was overcome by the effect of high-dose atropine on the sinoatrial node of the heart. In the present study, full MC blockade using atropine or glycopyrrolate elicited a similar tachycardia with no significant effect on ABP. Although the baseline LF density of ABP variability in the present investigation tended to be greater after atropine than glycopyrrolate, neither norepinephrine nor epinephrine concentration in the blood plasma was different before and after MC blockade or between the two different antimuscarinic drugs. These data suggest that the baseline sympathetic nerve activity was similar and that the difference in the baseline LF ABP oscillation (greater after atropine than glycopyrrolate) was not due to an atropine-related central effect on peripheral sympathetic nerve activity. This postulation is supported by a recent report (25) demonstrating that baseline LF ABP fluctuations without unusual maneuvers were not related to the directly measured MSNA. Furthermore, a study (12) of tetraplegic subjects who lost sympathetic neural control of vasomotor tone indicated that the LF spectral densities of RRI and LF ABP variability were correlated. Therefore, we postulated that the reduced baseline LF ABP oscillation after glycopyrrolate could be explained by a more significant decrease in LF RRI variability (Table 3 and 4). The difference in baseline LF RRI and ABP variability between atropine and glycopyrrolate was probably due to preantimuscarinic drug differences (Fig. 4) . We suggested that in a closed circuit without unusual hemodynamic disturbances, the LF ABP oscillation was significantly related to the LF spectral density of RRI variability at rest (Fig. 4) .
LF ABP oscillation during LBNP. Previously, Taylor et al. (24) demonstrated that the LF power of SBP and DBP variability were significantly increased following postural change from supine to 40°head-up tilt. When the HR response was fixed by paced rhythm, the increased LF DBP power during head-up tilt was significantly greater than that during sinus rhythm (24) . It has been demonstrated that the ABP variability around 0.1 Hz is significantly and positively correlated with the LF power density of MSNA over the variety of ABP range induced by nitroprusside and phenylephrine infusion (16) . Furthermore, it has been observed that prazosin, an ␣-adrenoceptor antagonist, reduces hemorrhage-augmented LF ABP variability (9, 15) . Oz et al. (15) compared the LF ABP variability between Wistar-Kyoto normotensive (WKY) rats and spontaneously hypertensive rats (SHR) before and after hemorrhage with and without prazosin or the angiotensin enzyme inhibitor captopril. They demonstrated that hemorrhage increased the ABP variability in both groups of rats (15) . Although the baseline ABP variability was significantly less in SHR than WKY rats, Fig. 7 . Group changes in mean intraradial arterial pressure (MAP) associated with cardiac output (CO) (left) and group changes in CO associated with stroke volume (SV) during minutes 2, 5, and 8 of Ϫ40 and Ϫ50 Torr LBNP (right) before and after parasympathetic blockade. Left: slope 0 indicates perfect vasoconstrictive compensation, i.e., decrease in CO without decrease in MAP. Before CO decreases by Ϫ20%, there is no hypotension. Slope 1 represents no vasoconstritive compensation, i.e., a unit decrease in MAP explained by unit decrease in CO. The rate of decrease in MAP per unit decrease in CO was similar before and after vagal blockade (slope ϭ 0.43). However, the decreases in CO and MAP are consistently greater (ANOVA, P Ͻ 0.05) after vagal blockade (left). Right: dashed line, no tachycardiac compensation, i.e., unit decreases in CO explained by unit decreases in SV. Tachycardiac compensation is seen at Ϫ20% ⌬CO before versus Ϫ30% ⌬CO after vagal blockade. The slope of %⌬CO/%⌬SV before parasympathetic blockade is 0.45, suggesting that 55% of the decreased SV is compensated by the tachycardiac response, which is diminished to 28% after vagal blockade (right).
the increase in ABP variability after hemorrhage was greater in SHR than WKY rats. This hemorrhageinduced augmentation in the ABP variability was diminished to a similar degree in SHR and WKY groups after prazosin or captopril administration, suggesting that activation of both the sympathetic nervous system and the renin-angiotensin system was required for the response to hemorrhage (15) . However, LF ABP oscillation is not significantly altered by blocking angiotensin-converting enzyme using enalaprilat in humans during a posture change from supine to 40°head-up tilt (23) or captopril in rats during hypotensive hemorrhage (9) .
The present study appeared in agreement with previous data in two interesting aspects. First, the LF ABP oscillation was significantly augmented during LBNP, the imposed stress of which was similar to hemorrhage or head-up tilt (Table 4 and Fig. 3 ), suggesting that this increase of LF ABP oscillation was probably related to the activation of the sympathetic nervous system. In the present study, plasma norepinephrine concentrations increased significantly during LBNP. Second, although before LBNP the baseline LF ABP oscillation tended to be lower after antimuscarinic agents (a simulated vagal dysfunction that commonly occurs with hypertension), the augmented LF ABP oscillation during LBNP tended to be greater with atropine or glycopyrrolate blockade. Furthermore, our data demonstrated that an increase in the LF ABP oscillation was significantly associated with the systemic hypotension developed during LBNP (Fig. 5) . We suggest that a greater LF ABP oscillation was synergistically integrated with a greater unloading of the arterial and cardiopulmonary baroreceptors in addition to the interaction with the activation of the sympathetic nervous system during LBNP. To our knowledge, this is the first study to demonstrate that vagal cardiac dysfunction, simulated by MC blockade with atropine or glycopyrrolate, significantly increases the LF density of ABP variability during orthostatic challenge and that this augmented ABP oscillation is an indication of ABP instability, which is associated with graded systemic hypotension.
The changes in LF RRI variability were not statistically associated with the change in LF ABP oscillation during graded LBNP as seen in the baseline condition (Fig. 4) . The mechanism for this discrepancy in the relation of LF ABP and RRI variability at rest and during LBNP remains unknown. We postulate that in a closed circuit such as the cardiovascular system, HR probably exerts a greater feed-forward influence on ABP oscillation through the conduit vessels at the baseline condition when the sympathetic activity is low. Thus the LF ABP oscillation was more related to the LF RRI variability at rest (Fig. 4) . During LBNP, this LF ABP oscillation was primarily modulated by the resistance vessels, which was accentuated by the interaction of the activated sympathetic nervous system.
Implication of the difference in LF ABP oscillation.
Application of LBNP has been commonly applied to simulate hemorrhage or orthostatic challenge. In this study, the augmented LF ABP oscillation during LBNP was attributed to changes in arterial vasomotion, modulated by the activation of the sympathetic nervous system. This enhanced vasomotion appeared to be related to systemic hypotension during LBNP, which in turn appeared to be an indication of ABP instability (Fig. 5) . Our data indicated that this ABP instability, evidenced by the augmented LF ABP oscillation during LBNP, was exacerbated after vagal cardiac blockade.
It has been established that LBNP-induced central hypovolemia is able to elicit systemic hypotension. However, we observed that central hypovolemia did not necessarily produce a proportional systemic hypotension with reflex vasoconstriction until the decrease in CO reached 20% (Fig. 7) . In the present study, the LBNP-induced rate of decrease in CO with MAP was identical before and after MC blockade, suggesting that the efficacy of reflex vasoconstriction was not compromised by antimuscarinic drugs during sustained LBNP. However, the decrease in MAP was consistently greater (ANOVA, P Ͻ 0.05) after MC blockade, which was explained by a greater decrease in CO during LBNP. These data implied that the susceptibility to systemic hypotension during sustained LBNP (simulated hemorrhage or orthostatic challenge) was exacerbated with MC blockade. This finding appears to confirm our previous conclusion that the integrity of vagal cardiac function was important in the maintenance of ABP at the onset of LBNP challenge (21) . This ABP instability during LBNP was not due to a lack of vasomotor responsiveness but was a result of the diminished HR reflex sensitivity after MC blockade. The diminished HR response induced a relatively greater decrease in CO, which explained a greater systemic hypotension (Fig. 7) . Subsequently, the vasomotor compensation mediated by neurohumoral factors was accentuated for the relatively greater unloading of the arterial and cardiopulmonary baroreceptors, which was related to ABP instability. Furthermore, this finding complements our previous report (21) by indicating that the vagal cardiac function is important in the maintenance of ABP stability during sustained orthostatic challenge.
Comparison of atropine and glycopyrrolate blockade. The present study suggested that after high-dose intravenous injection of atropine and glycopyrrolate, changes in HR and ABP during pressor and depressor response were not statistically different in young healthy humans. A relatively greater increase in plasma norepinephrine levels during LBNP occurred after atropine than after glycopyrrolate blockade. However, this difference did not reach statistical significance. The baseline LF ABP and RRI variabilities were lower after glycopyrrolate than atropine blockade. This antimuscarinic agent-related difference in the baseline LF ABP and RRI variability was related to the subject's individual control values, because the changes in baseline LF ABP and RRI variability (normalized with the values before the blockade) were not statistically different. The present study confirmed that the atropine inhibitory effect on the vagal cardiac function was dominant and that the efficacy of parasympathetic blockade using 40 g/kg atropine and 16 g/kg glycopyrrolate was equivalent.
In summary, our data demonstrate that vagal cardiac function plays an important role in cardiovascular homeostasis. Vagal cardiac dysfunction, whether simulated with parasympathetic blockade or associated with aging, diminishes the HR reflex buffering effect and augments the amplitude of ABP fluctuations during hypertensive and hypotensive stimuli. Therefore, chronic vagal dysfunction may impose damage to the end organs and can cause clinical syndromes. During LBNP-simulated hemorrhage or orthostatic challenge, the LF ABP oscillation is augmented progressively with a systemic hypotension. These data confirm that the augmented LF ABP oscillation is an indication of ABP instability, which appears to be accentuated after vagal cardiac blockade. The difference in full parasympathetic blockade using the antimuscarinic agents atropine and glycopyrrolate was nominal.
